Is CENTA undervalued?

AlphaMadera's AlphaVal page computes Central Garden & Pet Company's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag CENTA as undervalued, fairly valued, or overvalued.

What is Central Garden & Pet Company's fair value?

Fair value for CENTA is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value CENTA?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from CENTA's most recent reported fundamentals.

CENTA - Central Garden & Pet Company

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $53.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Undervalued Moderate

Trading 28.7% below fair value

Current Price $37.53

Bear Case $43.35 15.5% upside ($43.35 - $37.53) / $37.53 = 15.5% $3.09 × 14x P/E

Fair Value $52.64 40.3% upside ($52.64 - $37.53) / $37.53 = 40.3% $3.09 × 17x P/E

Bull Case $61.93 65.0% upside ($61.93 - $37.53) / $37.53 = 65.0% $3.09 × 20x P/E

Adjust Assumptions

P/E Multiple

17.0x

Adjusted EPS

3.09$

Key Value Driver

Normalized P/E multiple (17x base case)

Implied Market Multiple 12.1x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $53.00 from 13 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $52.64 per share.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples